Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 10/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | GAPDH | P04406 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HRAS | P01112 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15225534 | 1.00 | ADK (0.43) | ADKSLC29A1GAPDHLMNAALDH1A1 | |
| SCHEMBL13092007 | 1.00 | ADK (0.43) | ADKSLC29A1GAPDHLMNAALDH1A1 | |
| SCHEMBL16982301 | 1.00 | ADK (0.43) | ADKSLC29A1GAPDHLMNAALDH1A1 | |
| SCHEMBL21012864 | 1.00 | ADK (0.43) | ADKSLC29A1GAPDHLMNAALDH1A1 | |
| SCHEMBL14279133 | 0.91 | LMNA (0.37) | ADKGAPDHLMNAALDH1A1HRAS | |
| SCHEMBL16480871 | 0.91 | ADK (0.44) | ADKSLC29A1GAPDHLMNAALDH1A1 | |
| SCHEMBL13021360 | 0.90 | ADK (0.43) | ADKSLC29A1GAPDHLMNAALDH1A1 | |
| SCHEMBL2785729 | 0.90 | ADK (0.43) | ADKSLC29A1GAPDHLMNAALDH1A1 | |
| SCHEMBL16496818 | 0.90 | ADK (0.43) | ADKSLC29A1GAPDHLMNAALDH1A1 | |
| SCHEMBL24539010 | 0.85 | LMNA (0.45) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010135520-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100297079-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297079-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297079-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135520-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297079-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | HAVCR2, EIF2AK2, OAT | ADK 2308/4885SLC29A1 1367/4885GAPDH 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.